Esmail Mutahar. Al-Ezzi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Esmail Mutahar. Al-Ezzi has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Aaron Richard Hansen
Division of Cancer Services, Princess Alexandra Hospital, Metro South Health, Brisbane, Australia
19 shared publications - Olubukola Ayodele
University Hospitals of Leicester NHS Trust, Leicester, United Kingdom
17 shared publications - Abdulazeez Salawu
Department of Medicine, Division of Medical Oncology, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada
16 shared publications - Abha Anshu Gupta
Division of Haematology/Oncology Princess Margaret Cancer Center, The Hospital for Sick Children Toronto Ontario Canada
16 shared publications - Alberto Hernando-Calvo
Princess Margaret Cancer Centre, Toronto, ON, Canada
16 shared publications - Albiruni R. Abdul Razak
Toronto Sarcoma Program, Princess Margaret Cancer Center, Toronto, ON, Canada
16 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial.
Table S2: Best overall responses (iRECIST) of leiomyosarcoma patients on the DAPPER study
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial.
Table S2: Best overall responses (iRECIST) of leiomyosarcoma patients on the DAPPER study
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial.
Table S3: Representativeness of study participants
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial.
Table S3: Representativeness of study participants
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial.
Table S1: Best overall response (RECIST v1.1) of leiomyosarcoma patients on the DAPPER study
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial.
Table S1: Best overall response (RECIST v1.1) of leiomyosarcoma patients on the DAPPER study
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial.
Figure S1. Transcriptomic evaluation leiomyosarcoma patients in the TCGA dataset
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial.
Figure S1. Transcriptomic evaluation leiomyosarcoma patients in the TCGA dataset
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Safety, immunologic and clinical activity of Durvalumab in combination with Olaparib or Cediranib in advanced leiomyosarcoma: Results of the DAPPER clinical trial
Table S3: Representativeness of study participants
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Safety, immunologic and clinical activity of Durvalumab in combination with Olaparib or Cediranib in advanced leiomyosarcoma: Results of the DAPPER clinical trial
Table S3: Representativeness of study participants
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Safety, immunologic and clinical activity of Durvalumab in combination with Olaparib or Cediranib in advanced leiomyosarcoma: Results of the DAPPER clinical trial
Figure S1. Transcriptomic evaluation leiomyosarcoma patients in the TCGA dataset
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Safety, immunologic and clinical activity of Durvalumab in combination with Olaparib or Cediranib in advanced leiomyosarcoma: Results of the DAPPER clinical trial
Figure S1. Transcriptomic evaluation leiomyosarcoma patients in the TCGA dataset
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Safety, immunologic and clinical activity of Durvalumab in combination with Olaparib or Cediranib in advanced leiomyosarcoma: Results of the DAPPER clinical trial
Table S2: Best overall responses (iRECIST) of leiomyosarcoma patients on the DAPPER study
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Safety, immunologic and clinical activity of Durvalumab in combination with Olaparib or Cediranib in advanced leiomyosarcoma: Results of the DAPPER clinical trial
Table S2: Best overall responses (iRECIST) of leiomyosarcoma patients on the DAPPER study
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Safety, immunologic and clinical activity of Durvalumab in combination with Olaparib or Cediranib in advanced leiomyosarcoma: Results of the DAPPER clinical trial
Table S1: Best overall response (RECIST v1.1) of leiomyosarcoma patients on the DAPPER study
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Safety, immunologic and clinical activity of Durvalumab in combination with Olaparib or Cediranib in advanced leiomyosarcoma: Results of the DAPPER clinical trial
Table S1: Best overall response (RECIST v1.1) of leiomyosarcoma patients on the DAPPER study